Post-earnings recap
Reported
Thu, May 7, 2026
EPS actual
$-1.82
EPS est.
$-1.74
EPS surprise
-4.60%
1-day move
-2.02%
Nektar Therapeutics reported a larger-than-expected loss per share, which contributed to a 2.02% decline in the stock price following the earnings announcement. The company did not provide revenue figures, and there was no guidance update, leaving investors uncertain about future performance. The stock's reaction reflects concerns over the company's financial health and outlook.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.82 | $-1.60 | -4.60% |
| Revenue | — | $11M | — |
No transcript is on record, and the analysis is based solely on numerical results.
Nektar Therapeutics is a pharmaceutical company focused on developing innovative therapies for patients with serious diseases. With a market cap of $3 billion, it operates in the health care sector, addressing significant medical needs through its research and development efforts.
Last quarter
In the last quarter, Nektar reported an EPS of $-1.78, which was better than analysts' expectations of $-2.76, resulting in a positive surprise. However, revenue figures were not disclosed, leaving some uncertainty about overall performance.
EPS beat streak
1Q
EPS beat rate
63%
Avg EPS surprise
-155.56%
Avg 1-day reaction
-0.86%
Analysts are expecting Nektar to report a loss of $1.60 per share on revenues of $11 million this quarter. The market is closely watching how the company performs against these expectations.
Bull case
If Nektar can exceed revenue expectations and show signs of improving its financial performance, it could lead to a positive stock reaction.
Bear case
Conversely, if the company reports a larger loss than expected or lower revenue, it could raise concerns about its financial viability and lead to a negative stock reaction.
Key metrics to watch
EPS
$-1.60Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
$11MRevenue figures will provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
What is the expected revenue for this quarter, and how does it compare to the $11 million consensus?
Revenue figures will be crucial in assessing the company's market performance and growth potential.
Q2
Will the EPS come in better than the consensus estimate of $-1.60?
A smaller loss than expected could indicate improving financial health and investor confidence.
—
Est. EPS
$0.11
Est. Rev
$326M
Impl. Move
±7.3%
Why consensus could be wrong
The Street may be underestimating Nektar's potential for revenue growth due to recent positive surprises in EPS, which could indicate stronger underlying demand for its products.
Supporting evidence
Nektar has consistently surprised on EPS, with a 63% beat rate in the last 8 quarters.
The options market is pricing a larger move than historical averages, suggesting heightened expectations.
Recent trends in the pharmaceutical sector indicate a potential uptick in demand for innovative therapies.
Key risk
If the revenue exceeds $11 million, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
The market is weighing the potential for Nektar to improve its financial performance against the backdrop of previous earnings surprises.
Bull confirmed if
Reporting revenue above $11 million with an EPS better than $-1.60 would confirm the bull case.
Bear confirmed if
An EPS worse than $-1.60 and revenue below $6 million would confirm the bear case.
What the market is pricing for the move.
Implied Move
±5.50%
Historical Avg
±1.8%
The options market is pricing in a potential move of about 5.5% in either direction following the earnings report.
Options are pricing ±8.2% while NKTR has averaged ±1.8% over the last 8 prints — setup is pricing rich.
ATM IV
0.8%
30d HV
71.7%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: X of Y (Z%)
This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.6%, with a raw directional average of +0.8% (modestly positive historical bias).
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Nektar beats expectations, history suggests a positive stock reaction, with an average 1-day move of +1.25%.
In line / cautious
If results are in line with expectations, the stock may see muted movement as investors await further commentary.
Miss
If the company misses expectations, history suggests a potential downside move of around +0.54%.
The lines on the call that would change the story.